top of page

Prioritizing Minority Health
By IGT Scientific, Academic & Medical Advisory Council Chair Donna M. Christensen April is National Minority Health Month, an important...

IGT Statement on the Introduction of the Medicaid VBPs for Patients Act (H.R. 7389)
WASHINGTON, DC (April 5, 2022) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following...


Rare Disease Day Spotlight: Hope for HPP Patients
By Deborah Fowler, President & Founder of Soft Bones Rare Disease Day is a critical awareness day for many patients and families who are...


Changing the Way We Look at Huntington’s Disease
By IGT Patient Advocacy Advisory Council Member and Huntington's Disease Patient Advocate Seth Rotberg As we enter the third year of the...

IGT Statement on CMS Final Rule on Medicaid Value-based Purchasing Arrangements
WASHINGTON, DC (November18, 2021) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following...

IGT Statement on Senate's FY2022 Appropriations Bill
WASHINGTON, DC (August 6, 2021) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following...


Patient Perspective: Khrystal Davis
TX RARE works to improve access and health outcomes for nearly three million Texans living with rare diseases. Khrystal Davis, Founder of...


Howard University’s Dr. Sudha Sharma on the Importance of Addressing Health Inequities
IGT is proud to have the National Human Genome Center of Howard University as a member of our Scientific, Academic & Medical Council....

IGT Statement on ICER’s Analysis of the Accelerated Approval Pathway
WASHINGTON, DC (April 27, 2021) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following...

The Importance of National Minority Health Month
By IGT Scientific, Academic and Medical Council Chair Donna M. Christensen April is National Minority Health Month, a time to recognize...
bottom of page